AR089360A1 - Derivados de heterociclilo y su uso como moduladores del receptor d₂ de prostaglandina - Google Patents

Derivados de heterociclilo y su uso como moduladores del receptor d₂ de prostaglandina

Info

Publication number
AR089360A1
AR089360A1 ARP120104859A ARP120104859A AR089360A1 AR 089360 A1 AR089360 A1 AR 089360A1 AR P120104859 A ARP120104859 A AR P120104859A AR P120104859 A ARP120104859 A AR P120104859A AR 089360 A1 AR089360 A1 AR 089360A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
substituted
mono
alkyl
alkoxy
Prior art date
Application number
ARP120104859A
Other languages
English (en)
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of AR089360A1 publication Critical patent/AR089360A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Composiciones farmacéuticas que contienen estos compuestos; y a procesos para su preparación. Reivindicación 1: Un compuesto de la fórmula (1) donde: R¹ representa hidrógeno, alquilo C₁₋₄, alcoxi C₁₋₄, fluoroalquilo C₁₋₄, alquilsulfonilo C₁₋₄, halógeno o ciano; R² representa hidrógeno o halógeno; uno de R³, R⁴ y R⁵ representa carboxi-alquilo C₁₋₃, carboxi-ciclopropilo o carboxi-alcoxi C₁₋₃ y los otros dos representan, de manera independiente entre sí, hidrógeno, alcoxi C₁₋₄ o halógeno; R⁶ representa hidrógeno, alcoxi C₁₋₄ o halógeno; R⁷ representa hidrógeno, alquilo C₁₋₄, alcoxi C₁₋₄, cicloalquilo C₃₋₆-metoxi, cicloalquiloxi C₃₋₆, metoxi-etoxi, di-[alquilo C₁₋₂]-amino, fluoroalquilo C₁₋₄, fluoroalcoxi C₁₋₄, halógeno o alquilsulfonilo C₁₋₄; o R⁶ y R⁷ juntos representan metilendioxi o etilendioxi; R⁸ representa: alquilo C₂₋₅; alquilo C₁₋₅ que está mono- o di-sustituido donde los sustituyentes se seleccionan de manera independiente del grupo que consiste en hidroxi, alcoxi C₁₋₄, oxo, -NR⁹R¹⁰, cicloalquilo C₃₋₆ opcionalmente sustituido, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, heterociclilo opcionalmente sustituido, ariloxi opcionalmente sustituido, heteroariloxi opcionalmente sustituido o arilo-alcoxi C₁₋₂ opcionalmente sustituido; alquenilo C₃₋₅; alquenilo C₂₋₃ que está mono-sustituido con arilo opcionalmente sustituido o heteroarilo opcionalmente sustituido; alquinilo C₃₋₅; cicloalquilo C₃₋₆ que está no sustituido, mono-, di-, tri- o tetra-sustituido con metilo; mono-sustituido con oxo; mono-sustituido con arilo opcionalmente sustituido; o mono-sustituido con heteroarilo opcionalmente sustituido; o heterociclilo que está opcionalmente mono-sustituido con oxo; R⁹ representa alquilo C₁₋₄; R¹⁰ representa difenilmetilo opcionalmente sustituido; n representa 1 ó 2; m representa 1 ó 2; y Z representa -NH-, -O- o un enlace; o una sal de dicho compuesto.
ARP120104859A 2011-12-21 2012-12-20 Derivados de heterociclilo y su uso como moduladores del receptor d₂ de prostaglandina AR089360A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IB2011055866 2011-12-21

Publications (1)

Publication Number Publication Date
AR089360A1 true AR089360A1 (es) 2014-08-20

Family

ID=47678924

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120104859A AR089360A1 (es) 2011-12-21 2012-12-20 Derivados de heterociclilo y su uso como moduladores del receptor d₂ de prostaglandina

Country Status (14)

Country Link
US (1) US9255090B2 (es)
EP (1) EP2794563B1 (es)
JP (1) JP6097765B2 (es)
KR (1) KR20140107550A (es)
CN (1) CN104011021B (es)
AR (1) AR089360A1 (es)
AU (1) AU2012356076A1 (es)
BR (1) BR112014015081A8 (es)
CA (1) CA2858328A1 (es)
ES (1) ES2624379T3 (es)
MX (1) MX2014007688A (es)
RU (1) RU2014129613A (es)
TW (1) TW201331179A (es)
WO (1) WO2013093842A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2876808A1 (en) 2012-07-05 2014-01-09 Actelion Pharmaceuticals Ltd 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
JO3316B1 (ar) 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل
AR099789A1 (es) 2014-03-24 2016-08-17 Actelion Pharmaceuticals Ltd Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB238854A (en) 1924-08-20 1926-02-11 Walter Martin Cross Improvements in or relating to turbines
US5236934A (en) * 1992-08-26 1993-08-17 E. I. Du Pont De Nemours And Company 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders
DE60215000T2 (de) 2001-05-23 2007-08-09 Merck Frosst Canada & Co, Kirkland Dihydropyrroloil[1,2-a]indol- und Tetrahydropyridol[1,2-a]indol-Derivate als Prostaglandin-D2-Rezeptor-Antagonisten
SE0103644D0 (sv) * 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic isoquinoline compounds
WO2003097598A1 (fr) 2002-05-16 2003-11-27 Shionogi & Co., Ltd. Composé comprenant un antagonisme du récepteur de pdg2
JPWO2003097042A1 (ja) 2002-05-16 2005-09-15 塩野義製薬株式会社 Ｐｇｄ２受容体拮抗剤
GB2388540A (en) 2002-05-17 2003-11-19 Bayer Ag New use of Ramatroban
WO2004032848A2 (en) 2002-10-04 2004-04-22 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
EP1413306A1 (en) 2002-10-21 2004-04-28 Warner-Lambert Company LLC Tetrahydroquinoline derivatives as CRTH2 antagonists
CA2500083A1 (en) 2002-10-21 2004-04-29 Warner-Lambert Company Llc Tetrahydroquinoline derivatives as crth2 antagonists
CN100406007C (zh) 2002-12-20 2008-07-30 安姆根有限公司 哮喘和过敏性炎症调节剂
EP1435356A1 (en) 2003-01-06 2004-07-07 Warner-Lambert Company LLC Quinoline derivatives as CRTH2 antagonists
SE0301009D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
DK1471057T3 (da) 2003-04-25 2006-05-15 Actimis Pharmaceuticals Inc Pyrimidinyleddikesyrederivater, der er egnede til behandlingen af sygdomme medieret af CRTH2
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
PL1718649T3 (pl) 2004-01-31 2009-11-30 Actimis Pharmaceuticals Inc Pochodne kwasu imidazo[1,2-c]pirymidynylooctowego
PT1732898E (pt) 2004-03-12 2008-04-07 Analytecon Sa Derivados de tetrahidroisoquinolina e tetrahidrobenzazepina como inibidores igf-1r
AR048528A1 (es) 2004-04-07 2006-05-03 Millennium Pharm Inc Compuestos derivados de quinolina como antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias y composiciones farmacéuticas que los contienen.
US20090170897A1 (en) 2004-04-20 2009-07-02 Pfizer, Inc. Method of Treating Neuropathic Pain
GB0409921D0 (en) 2004-05-04 2004-06-09 Novartis Ag Organic compounds
EA014729B1 (ru) 2004-05-29 2011-02-28 7ТиЭм ФАРМА А/С Лиганды crth2 рецептора и их применение
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
GB0422057D0 (en) 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
GT200500284A (es) 2004-10-15 2006-03-27 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
PL1817282T3 (pl) 2004-11-23 2011-11-30 Astrazeneca Ab Pochodne kwasu fenoksyoctowego użyteczne do leczenia chorób układu oddechowego
GB0427381D0 (en) 2004-12-14 2005-01-19 Novartis Ag Organic compounds
DOP2006000016A (es) 2005-01-26 2006-07-31 Aventis Pharma Inc 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2.
US7951950B2 (en) 2005-02-24 2011-05-31 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
GB0510585D0 (en) 2005-05-24 2005-06-29 Novartis Ag Organic compounds
GB0510584D0 (en) 2005-05-24 2005-06-29 Novartis Ag Organic compounds
ES2372701T3 (es) 2005-07-22 2012-01-25 Shionogi & Co., Ltd. Derivado de indol que tiene actividad antagonista del receptor de pgd2.
EP1911759A4 (en) 2005-07-22 2010-07-21 Shionogi & Co AZAINDOL DERIVATIVE ANTAGONISTIC EFFECT ON PGD2 RECEPTOR
US8143285B2 (en) 2005-09-06 2012-03-27 Shionogi & Co., Ltd. Indolecarboxylic acid derivative having PGD2 receptor antagonistic activity
BRPI0616574A2 (pt) 2005-09-27 2009-11-24 Shionogi & Co derivado de sulfonamida tendo atividade antagonìstica de receptor de pgd2
US7858640B2 (en) 2005-09-30 2010-12-28 Pulmagen Therapeutics (Asthma) Limited Quinolines and their therapeutic use
US8148572B2 (en) 2005-10-06 2012-04-03 Astrazeneca Ab Compounds
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
US20080255150A1 (en) 2005-11-05 2008-10-16 Astrazeneca Ab Novel Compounds
WO2007062678A1 (en) 2005-11-29 2007-06-07 7Tm Pharma A/S Phenoxyacetic acid derivatives as crth2 receptor ligands
GB0524428D0 (en) 2005-11-30 2006-01-11 7Tm Pharma As Medicinal use of receptor ligands
US20080004272A1 (en) 2006-04-10 2008-01-03 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
DOP2007000068A (es) 2006-04-12 2007-10-31 Sanofi Aventis Us Llc Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2
WO2007143745A2 (en) 2006-06-09 2007-12-13 Icos Corporation Substituted phenyl acetic acids as dp-2 antagonists
CA2654927A1 (en) 2006-06-09 2007-12-21 Icos Corporation Substituted phenyl acetic acids as dp-2 antagonists
GB0611781D0 (en) 2006-06-14 2006-07-26 Argenta Discovery Ltd 2-Oxo-2H-Chromene Compounds
AR064346A1 (es) 2006-12-14 2009-04-01 Astellas Pharma Inc Compuesto de oxicarbonilo
BRPI0721516A2 (pt) 2007-03-29 2013-01-15 Argenta Discovery Ltd derivados de quinolina como ligantes de receptor crth2
EP2139881B1 (en) 2007-04-04 2011-11-09 Pulmagen Therapeutics (Asthma) Limited Quinolines and their therapeutic use
UA100983C2 (ru) 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
WO2009061730A2 (en) 2007-11-05 2009-05-14 Array Biopharma Inc. 4-heteroaryl-substituted phenoxyphenylacetic acid
GB0722055D0 (en) 2007-11-09 2007-12-19 Argenta Discovery Ltd Compounds
JP2011508787A (ja) 2008-01-07 2011-03-17 リガンド・ファーマシューティカルズ・インコーポレイテッド 炎症疾患治療に有用な２−フェニルフェノキシ酢酸
US20110098352A1 (en) 2008-02-01 2011-04-28 Amira Pharmaceuticals, Inc. N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
WO2009099902A1 (en) * 2008-02-01 2009-08-13 Amira Pharmaceuticals, Inc. N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
JP2011512359A (ja) 2008-02-14 2011-04-21 アミラ ファーマシューティカルズ，インク． プロスタグランジンｄ２受容体のアンタゴニストとしての環式ジアリールエーテル化合物
US8497381B2 (en) 2008-02-25 2013-07-30 Panmira Pharmaceuticals, Llc Antagonists of prostaglandin D2 receptors
EP2268611A2 (en) 2008-04-02 2011-01-05 Amira Pharmaceuticals, Inc. Aminoalkylphenyl antagonists of prostaglandin d2 receptors
JP5531370B2 (ja) 2008-07-03 2014-06-25 パンミラ ファーマシューティカルズ，エルエルシー． プロスタグランジンｄ２受容体のアンタゴニスト
EP2321268A2 (en) 2008-08-15 2011-05-18 F. Hoffmann-La Roche AG Bi-aryl aminotetralines
CA2732210A1 (en) 2008-08-15 2010-02-18 F. Hoffmann-La Roche Ag Monoaryl aminotetralines
WO2010018109A2 (en) 2008-08-15 2010-02-18 F. Hoffmann-La Roche Ag Substituted aminotetralines
WO2010042652A2 (en) 2008-10-08 2010-04-15 Amira Pharmaceuticals, Inc. Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
NZ591914A (en) 2008-11-17 2013-04-26 Hoffmann La Roche Naphthylacetic acids
EP2393492A1 (en) 2009-02-09 2011-12-14 Boehringer Ingelheim International GmbH New pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
JP2012517454A (ja) 2009-02-12 2012-08-02 メルク セローノ ソシエテ アノニム フェノキシ酢酸誘導体
WO2010102154A2 (en) 2009-03-05 2010-09-10 Ligand Pharmaceuticals Incorporated Biaryl oxyacetic acid compounds
GB0907284D0 (en) * 2009-04-28 2009-06-10 Queen Mary & Westfield College Compounds for inducing cellular apoptosis
WO2011002814A2 (en) 2009-06-30 2011-01-06 Ligand Pharmaceuticals Inc. Biaryl oxyacetic acid compounds
JP2013500978A (ja) 2009-07-31 2013-01-10 パンミラ ファーマシューティカルズ，エルエルシー． Ｄｐ２受容体アンタゴニストの眼の医薬組成物
CN102596193A (zh) 2009-07-31 2012-07-18 潘米拉制药公司 Dp2受体拮抗的皮肤调配物
MX2012001542A (es) 2009-08-05 2012-06-19 Panmira Pharmaceuticals Llc Antagonista dp2 y usos del mismo.
WO2011055270A1 (en) 2009-11-04 2011-05-12 Wyeth Llc Indole based receptor crth2 antagonists
CN102958914B (zh) 2010-07-05 2015-05-27 埃科特莱茵药品有限公司 1-苯基取代的杂环衍生物及其作为前列腺素d2受体调节剂的用途
CN103702985B (zh) 2010-12-23 2016-02-17 默沙东公司 作为crth2受体调节剂的喹喔啉和氮杂喹喔啉
PL2671869T3 (pl) * 2011-02-02 2016-09-30 Pochodna tetrahydroizochinoliny
BR112014009108A2 (pt) 2011-10-25 2017-04-18 Shionogi & Co derivado heterocíclico tendo atividade antagonista de receptor de pgd2
US8691993B2 (en) 2011-12-12 2014-04-08 Hoffmann-La Roche Inc. Piperidinyl naphthylacetic acids
US9000044B2 (en) 2012-02-28 2015-04-07 Hoffmann-La Roche Inc. Substituted naphthylacetic acids
CA2876808A1 (en) 2012-07-05 2014-01-09 Actelion Pharmaceuticals Ltd 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators

Also Published As

Publication number Publication date
BR112014015081A2 (pt) 2017-06-13
MX2014007688A (es) 2014-07-28
EP2794563A1 (en) 2014-10-29
JP2015502399A (ja) 2015-01-22
JP6097765B2 (ja) 2017-03-15
KR20140107550A (ko) 2014-09-04
US9255090B2 (en) 2016-02-09
AU2012356076A1 (en) 2014-08-14
RU2014129613A (ru) 2016-02-10
CN104011021A (zh) 2014-08-27
BR112014015081A8 (pt) 2017-06-13
EP2794563B1 (en) 2017-02-22
CN104011021B (zh) 2016-08-24
WO2013093842A1 (en) 2013-06-27
ES2624379T3 (es) 2017-07-14
US20150252036A1 (en) 2015-09-10
TW201331179A (zh) 2013-08-01
CA2858328A1 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
AR114064A2 (es) Compuestos insecticidas basados en derivados de isoxazolina
AR100033A1 (es) Compuestos y composiciones para inhibir la actividad de shp2
AR108710A1 (es) Compuestos modulares de fxr (nr1h4)
AR089671A1 (es) 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
AR088828A1 (es) DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3
AR111689A1 (es) Tienopiridinas y benzotiofenos útiles como inhibidores de irak4
AR090488A1 (es) Derivados de n-ciclobutilbenzamida, un proceso para su obtencion, intermediarios para su sintesis, composiciones pesticidas y farmaceuticas que los comprenden y metodos para controlar daños debidos a una plaga y/u hongos
AR101815A1 (es) Compuestos y composiciones como inhibidores de quinasa
AR094314A1 (es) Inhibidores de fosfatidilinositol 3-cinasa
AR090967A1 (es) Picolinamidas macrociclicas como fungicidas
AR099823A1 (es) Compuestos bicíclicos de 7 eslabones
AR102799A1 (es) Profármacos de agonistas fenólicos de trpv1
AR095311A1 (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
AR093921A1 (es) Derivados de indol carboxamida como antagonistas del receptor p2x7
AR093818A1 (es) Compuesto de 1-(bencil sustituido)piperazina sustituida
AR091654A1 (es) COMPUESTOS QUE CONTIENEN BIARILO COMO AGONISTAS INVERSOS DE RECEPTORES ROR-g
AR088829A1 (es) DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3
AR090945A1 (es) Moduladores de la via del complemento y usos de los mismos
AR100418A1 (es) Compuestos y composiciones para inducir condrogénesis
AR092684A1 (es) Compuestos de sulfonamida sustituidos
AR102217A1 (es) Derivados de benzotiofenilo sustituidos como agonistas de gpr40 para el tratamiento de la diabetes tipo ii
AR089753A1 (es) Derivados de amida heterociclicos como antagonistas del receptor p2x7
AR103742A1 (es) Derivados de trifluorometilpropanamida
AR091185A1 (es) Derivados de 1,2,4-triazol
AR087274A1 (es) Derivados de amidas heterociclicas como antagonistas de receptores p2x7

Legal Events

Date Code Title Description
FB Suspension of granting procedure